Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT

B. Dholaria; B.N. Savani; M. Labopin; L. Luznik; A. Ruggeri; S. Mielke; M.M. Al Malki; P. Kongtim; E. Fuchs; X.-J. Huang; F. Locatelli; F. Aversa; L. Castagna; A. Bacigalupo; M. Martelli; D. Blaise; P.B. Soussan; Y. Arnault; R. Handgretinger; D.-C. Roy; P. O'Donnell; A. Bashey; S. Solomon; R. Romee; P. Lewalle; J. Gayoso; M. Maschan; H.M. Lazarus; K. Ballen; S. Giebel; F. Baron; F. Ciceri; J. Esteve; N.-C. Gorin; A. Spyridonidis; C. Schmid; S.O. Ciurea; A. Nagler; M. Mohty

doi:10.3324/haematol.2019.219790

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT

B. Dholaria, B.N. Savani, M. Labopin, L. Luznik, A. Ruggeri, S. Mielke, M.M. Al Malki, P. Kongtim, E. Fuchs, X.-J. Huang, F. Locatelli, F. Aversa, L. Castagna, A. Bacigalupo, M. Martelli, D. Blaise, P.B. Soussan, Y. Arnault, R. Handgretinger, D.-C. RoyP. O'Donnell, A. Bashey, S. Solomon, R. Romee, P. Lewalle, J. Gayoso, M. Maschan, H.M. Lazarus, K. Ballen, S. Giebel, F. Baron, F. Ciceri, J. Esteve, N.-C. Gorin, A. Spyridonidis, C. Schmid, S.O. Ciurea, A. Nagler, M. Mohty

Research output: Contribution to journal › Article › peer-review

Abstract

Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice. © 2020 Ferrata Storti Foundation

Original language	English
Pages (from-to)	47-58
Number of pages	12
Journal	Haematologica
Volume	105
Issue number	1
DOIs	https://doi.org/10.3324/haematol.2019.219790
Publication status	Published - 2020

Keywords

granulocyte colony stimulating factor
HLA antigen
acute leukemia
acute lymphoblastic leukemia
bone marrow aplasia
bone marrow transplantation
chemotherapy
chimera
chronic graft versus host disease
clinical practice
disease free survival
donor lymphocyte infusion
follow up
haploidentical donor
hematopoietic stem cell transplantation
human
immunosuppressive treatment
minimal residual disease
mortality
mutation
overall survival
peripheral blood stem cell
prophylaxis
Review
risk factor

Access to Document

10.3324/haematol.2019.219790

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075742887&doi=10.3324%2fhaematol.2019.219790&partnerID=40&md5=e0133983ef23dde1c9f44f60267bc40c

Cite this

Dholaria, B., Savani, B. N., Labopin, M., Luznik, L., Ruggeri, A., Mielke, S., Al Malki, M. M., Kongtim, P., Fuchs, E., Huang, X-J., Locatelli, F., Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Soussan, P. B., Arnault, Y., Handgretinger, R., ... Mohty, M. (2020). Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 105(1), 47-58. https://doi.org/10.3324/haematol.2019.219790

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT. / Dholaria, B.; Savani, B.N.; Labopin, M.; Luznik, L.; Ruggeri, A.; Mielke, S.; Al Malki, M.M.; Kongtim, P.; Fuchs, E.; Huang, X.-J.; Locatelli, F.; Aversa, F.; Castagna, L.; Bacigalupo, A.; Martelli, M.; Blaise, D.; Soussan, P.B.; Arnault, Y.; Handgretinger, R.; Roy, D.-C.; O'Donnell, P.; Bashey, A.; Solomon, S.; Romee, R.; Lewalle, P.; Gayoso, J.; Maschan, M.; Lazarus, H.M.; Ballen, K.; Giebel, S.; Baron, F.; Ciceri, F.; Esteve, J.; Gorin, N.-C.; Spyridonidis, A.; Schmid, C.; Ciurea, S.O.; Nagler, A.; Mohty, M.

In: Haematologica, Vol. 105, No. 1, 2020, p. 47-58.

Research output: Contribution to journal › Article › peer-review

Dholaria, B, Savani, BN, Labopin, M, Luznik, L, Ruggeri, A, Mielke, S, Al Malki, MM, Kongtim, P, Fuchs, E, Huang, X-J, Locatelli, F, Aversa, F, Castagna, L , Bacigalupo, A , Martelli, M, Blaise, D, Soussan, PB, Arnault, Y, Handgretinger, R, Roy, D-C, O'Donnell, P, Bashey, A, Solomon, S, Romee, R, Lewalle, P, Gayoso, J, Maschan, M, Lazarus, HM, Ballen, K, Giebel, S, Baron, F, Ciceri, F, Esteve, J, Gorin, N-C, Spyridonidis, A, Schmid, C, Ciurea, SO, Nagler, A & Mohty, M 2020, 'Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT', Haematologica, vol. 105, no. 1, pp. 47-58. https://doi.org/10.3324/haematol.2019.219790

Dholaria, B. ; Savani, B.N. ; Labopin, M. ; Luznik, L. ; Ruggeri, A. ; Mielke, S. ; Al Malki, M.M. ; Kongtim, P. ; Fuchs, E. ; Huang, X.-J. ; Locatelli, F. ; Aversa, F. ; Castagna, L. ; Bacigalupo, A. ; Martelli, M. ; Blaise, D. ; Soussan, P.B. ; Arnault, Y. ; Handgretinger, R. ; Roy, D.-C. ; O'Donnell, P. ; Bashey, A. ; Solomon, S. ; Romee, R. ; Lewalle, P. ; Gayoso, J. ; Maschan, M. ; Lazarus, H.M. ; Ballen, K. ; Giebel, S. ; Baron, F. ; Ciceri, F. ; Esteve, J. ; Gorin, N.-C. ; Spyridonidis, A. ; Schmid, C. ; Ciurea, S.O. ; Nagler, A. ; Mohty, M. / Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT. In: Haematologica. 2020 ; Vol. 105, No. 1. pp. 47-58.

@article{d1625d0bc8d64087a57e6d9a78491360,

title = "Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT",

abstract = "Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice. {\textcopyright} 2020 Ferrata Storti Foundation",

keywords = "granulocyte colony stimulating factor, HLA antigen, acute leukemia, acute lymphoblastic leukemia, bone marrow aplasia, bone marrow transplantation, chemotherapy, chimera, chronic graft versus host disease, clinical practice, disease free survival, donor lymphocyte infusion, follow up, haploidentical donor, hematopoietic stem cell transplantation, human, immunosuppressive treatment, minimal residual disease, mortality, mutation, overall survival, peripheral blood stem cell, prophylaxis, Review, risk factor",

author = "B. Dholaria and B.N. Savani and M. Labopin and L. Luznik and A. Ruggeri and S. Mielke and {Al Malki}, M.M. and P. Kongtim and E. Fuchs and X.-J. Huang and F. Locatelli and F. Aversa and L. Castagna and A. Bacigalupo and M. Martelli and D. Blaise and P.B. Soussan and Y. Arnault and R. Handgretinger and D.-C. Roy and P. O'Donnell and A. Bashey and S. Solomon and R. Romee and P. Lewalle and J. Gayoso and M. Maschan and H.M. Lazarus and K. Ballen and S. Giebel and F. Baron and F. Ciceri and J. Esteve and N.-C. Gorin and A. Spyridonidis and C. Schmid and S.O. Ciurea and A. Nagler and M. Mohty",

note = "Cited By :11 Export Date: 11 March 2021 CODEN: HAEMA Correspondence Address: Dholaria, B.; Department of Hematology-Oncology, United States; email: bhagirathbhai.r.dholaria@vumc.org Funding text 1: The authors would like to thank Vidya B. Pai, MD, for assistance with proofreading.",

year = "2020",

doi = "10.3324/haematol.2019.219790",

language = "English",

volume = "105",

pages = "47--58",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

TY - JOUR

T1 - Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT

AU - Dholaria, B.

AU - Savani, B.N.

AU - Labopin, M.

AU - Luznik, L.

AU - Ruggeri, A.

AU - Mielke, S.

AU - Al Malki, M.M.

AU - Kongtim, P.

AU - Fuchs, E.

AU - Huang, X.-J.

AU - Locatelli, F.

AU - Aversa, F.

AU - Castagna, L.

AU - Bacigalupo, A.

AU - Martelli, M.

AU - Blaise, D.

AU - Soussan, P.B.

AU - Arnault, Y.

AU - Handgretinger, R.

AU - Roy, D.-C.

AU - O'Donnell, P.

AU - Bashey, A.

AU - Solomon, S.

AU - Romee, R.

AU - Lewalle, P.

AU - Gayoso, J.

AU - Maschan, M.

AU - Lazarus, H.M.

AU - Ballen, K.

AU - Giebel, S.

AU - Baron, F.

AU - Ciceri, F.

AU - Esteve, J.

AU - Gorin, N.-C.

AU - Spyridonidis, A.

AU - Schmid, C.

AU - Ciurea, S.O.

AU - Nagler, A.

AU - Mohty, M.

N1 - Cited By :11 Export Date: 11 March 2021 CODEN: HAEMA Correspondence Address: Dholaria, B.; Department of Hematology-Oncology, United States; email: bhagirathbhai.r.dholaria@vumc.org Funding text 1: The authors would like to thank Vidya B. Pai, MD, for assistance with proofreading.

PY - 2020

Y1 - 2020

N2 - Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice. © 2020 Ferrata Storti Foundation

AB - Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice. © 2020 Ferrata Storti Foundation

KW - granulocyte colony stimulating factor

KW - HLA antigen

KW - acute leukemia

KW - acute lymphoblastic leukemia

KW - bone marrow aplasia

KW - bone marrow transplantation

KW - chemotherapy

KW - chimera

KW - chronic graft versus host disease

KW - clinical practice

KW - disease free survival

KW - donor lymphocyte infusion

KW - follow up

KW - haploidentical donor

KW - hematopoietic stem cell transplantation

KW - human

KW - immunosuppressive treatment

KW - minimal residual disease

KW - mortality

KW - mutation

KW - overall survival

KW - peripheral blood stem cell

KW - prophylaxis

KW - Review

KW - risk factor

U2 - 10.3324/haematol.2019.219790

DO - 10.3324/haematol.2019.219790

M3 - Article

VL - 105

SP - 47

EP - 58

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT

Abstract

Keywords

Access to Document

Fingerprint

Cite this